[
    [
        {
            "time": "2021-08-07",
            "orginal_text": "锂电领跑比亚迪市值暴增 生物疫苗恐复星医药重挫",
            "features": {
                "keywords": [
                    "锂电",
                    "比亚迪",
                    "市值暴增",
                    "生物疫苗",
                    "复星医药",
                    "重挫"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "锂电领跑比亚迪市值暴增 生物疫苗恐复星医药重挫",
            "scores": {
                "News_content": "锂电领跑比亚迪市值暴增 生物疫苗恐复星医药重挫",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-08-07",
            "orginal_text": "千亿大白马股东刚减持完又宣布增持，能稳住吗？",
            "features": {
                "keywords": [
                    "千亿大白马",
                    "减持",
                    "增持"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "千亿大白马股东刚减持完又宣布增持，能稳住吗？",
            "scores": {
                "News_content": "千亿大白马股东刚减持完又宣布增持，能稳住吗？",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-07",
            "orginal_text": "上市公司正面负面新闻2021年8月7日星期六",
            "features": {
                "keywords": [
                    "上市公司",
                    "正面负面新闻"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "上市公司正面负面新闻2021年8月7日星期六",
            "scores": {
                "News_content": "上市公司正面负面新闻2021年8月7日星期六",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 1,
                "Headline_Structure": 3,
                "Source_Recency": 1
            }
        },
        {
            "time": "2021-08-07",
            "orginal_text": "长春高新：公司贯彻以医药为主、房地产为辅的产业发展定位，推进地产板块平稳发展，同时无加码房地产业务安排",
            "features": {
                "keywords": [
                    "长春高新",
                    "医药",
                    "房地产",
                    "产业定位",
                    "平稳发展"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "长春高新：公司贯彻以医药为主、房地产为辅的产业发展定位，推进地产板块平稳发展，同时无加码房地产业务安排",
            "scores": {
                "News_content": "长春高新：公司贯彻以医药为主、房地产为辅的产业发展定位，推进地产板块平稳发展，同时无加码房地产业务安排",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-08-07",
            "orginal_text": "长春高新：公司预计短期内生长激素产品不会进入国家集采，目前只有个别省份拟进行集采事项，相对来说影响较小",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "国家集采",
                    "影响较小"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "长春高新：公司预计短期内生长激素产品不会进入国家集采，目前只有个别省份拟进行集采事项，相对来说影响较小",
            "scores": {
                "News_content": "长春高新：公司预计短期内生长激素产品不会进入国家集采，目前只有个别省份拟进行集采事项，相对来说影响较小",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-07",
            "orginal_text": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利，上述两项专利申请日期为2008年，保护期20年",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "金赛药业",
                    "发明专利",
                    "专利保护期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利，上述两项专利申请日期为2008年，保护期20年",
            "scores": {
                "News_content": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利，上述两项专利申请日期为2008年，保护期20年",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]